Thirty-three patients with advanced or metastatic urothelial cancer with at least 1% PD-L1 expression in tumor cells or stroma were enrolled and treated with 10 mg/kg intravenous pembrolizumab every two weeks, until progressive disease or unacceptable toxicity. Here, CD274 is linked to neoplasm.